Here is a brief summary based on the DOI you provided:
### Article Title:
**Tanshinone I inhibits doxorubicin-induced cardiotoxicity by regulating Nrf2 signaling pathway**
### DOI:
10.1016/j.phymed.2022.154439
### Journal:
This article was published in the journal *Phytomedicine*. It likely explores how **Tanshinone I**, a compound derived from *Salvia miltiorrhiza* (Danshen), mitigates the cardiotoxic effects of **doxorubicin**, a widely used chemotherapy drug, by modulating the **Nrf2 signaling pathway**, which plays a key role in oxidative stress responses.
### Key Points:
1. **Doxorubicin-Induced Cardiotoxicity**:
- Doxorubicin is an effective cancer treatment but causes serious side effects, including **cardiotoxicity**, primarily through oxidative damage to heart tissues.
2. **Role of Nrf2 Pathway**:
- The **Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)** signaling pathway is crucial in protecting cells against oxidative stress by promoting antioxidant responses.
3. **Effect of Tanshinone I**:
- Tanshinone I potentially alleviates cardiotoxicity by activating Nrf2 signaling, enhancing antioxidant defenses, and reducing oxidative damage in cardiac cells.
- It may reduce inflammation, apoptosis, and oxidative stress, contributing to protective effects on the heart.
### Implications:
The study provides insights into the therapeutic potential of Tanshinone I as a natural compound for preventing or reducing doxorubicin-induced cardiac damage. This could be significant for improving the safety profile of doxorubicin-based cancer therapies.
If you'd like specific details from the article (such as experimental methods, results, or conclusions), you can access it directly via its DOI link, typically through platforms like ScienceDirect. Let me know if you need guidance accessing it! |
求助已关闭
30